Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Background: Sleep disturbance is common in dementia and often treated with Z-drugs (zopiclone, zaleplon, and zolpidem). While some observational studies suggest that Z-drugs are associated with adverse events such as falls and fracture risks in older people, this has not been studied in dementia. Methods: We used data from 27,090 patients diagnosed with dementia between January 2000 and March 2016 from the Clinical Practice Research Datalink linked to Hospital Episodes Statistics data in England. We compared adverse events for 3532 patients newly prescribed Z-drugs by time-varying dosage to (1) 1833 non-sedative-users with sleep disturbance; (2) 10,214 non-sedative-users with proximal GP consultation matched on age, sex, and antipsychotic use; and (3) 5172 patients newly prescribed benzodiazepines. We defined higher dose Z-drugs and benzodiazepines as prescriptions equivalent to ≥ 7.5 mg zopiclone or > 5 mg diazepam daily. Cox regression was used to estimate hazard ratios (HRs) for incident fracture, hip fracture, fall, mortality, acute bacterial infection, ischaemic stroke/transient ischaemic attack, and venous thromboembolism over a 2-year follow-up, adjusted for demographic- and health-related covariates. Results: The mean (SD) age of patients was 83 (7.7) years, and 16,802 (62%) were women. Of 3532 patients prescribed Z-drugs, 584 (17%) were initiated at higher doses. For patients prescribed higher dose Z-drugs relative to non-users with sleep disturbance, the HRs (95% confidence interval) for fractures, hip fractures, falls, and ischaemic stroke were 1.67 (1.13–2.46), 1.96 (1.16–3.31), 1.33 (1.06–1.66), and 1.88 (1.14–3.10), respectively. We observed similar associations when compared to non-sedative-users with proximal GP consultation. Minimal or inconsistent excess risks were observed at ≤ 3.75 mg zopiclone or equivalent daily, and for mortality, infection, and venous thromboembolism. We observed no differences in adverse events for Z-drugs compared to benzodiazepines, except lower mortality rates with Z-drugs (HR [95% confidence interval] of 0.73 [0.64–0.83]). Conclusions: Higher dose Z-drug use in dementia is associated with increased fracture and stroke risks, similar or greater to that for higher dose benzodiazepines. Higher dose Z-drugs should be avoided, if possible, in people living with dementia, and non-pharmacological alternatives preferentially considered. Prescriptions for higher dose Z-drugs in dementia should be regularly reviewed. Trial registration: ENCePP e-register of studies,EUPAS18006
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In older adults, psychotropic use has been associated with the risk of severe adverse effects such as falls [13–18], stroke [17, 19–22] and mortality [13, 23–25].”
From Stakeholders' views on the use of psychotropic medication in older people: a systematic review (2022) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Self-citationMultiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792 · cited 1×
“Multiple imputation by chained equations was used to impute missing values of BMI, smoking, alcohol use, residence, ethnicity, and blood pressure (see Additional file 4 for details) [32].”
MethodProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“The proportional hazards assumption was checked using Schoenfeld residuals [28].”
MethodBy the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15767 · Cited by 3,163
Regression standard errors in clustered samples
Rogers, W. H. (1993) · Stata technical bulletin · Cited by 2,694
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 2×
“We excluded patients with < 3 months of ‘up-to-standard’ (research quality) data or with severe mental illness or Down syndrome before dementia diagnosis (codes in Additional file 1) [21].”
BackgroundThe American Geriatrics Society 2012 Beers Criteria Update Expert Panel (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03923.x · Cited by 2,578
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
Body mass index as a predictor of fracture risk: A meta-analysis
De Laet, C., Kanis, J. A., Odén, A., Johanson, H., Johnell, O., Delmas, P., Eisman, J. A., Kroger, H., Fujiwara, S., Garnero, P., et al. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1863-y · Cited by 1,622
Research works printed but not linked: 1
- Patel V. Deaths registered in England and Wales: 2017. London: Office for National Statistics; 2018.
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Self-citationLong-term use of benzodiazepines in chronic insomnia: a European perspective
Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 121
Ngcobo, N. N. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01466-0 · Cited by 199
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
Sleep disorders and risk of alzheimer's disease: A two-way road
Lacerda, R. A. V., Desio, J. A. F., Kammers, C. M., Henkes, S. F. C., de Sá, M. F., de Souza, E. F., da Silva, D. M., Gusmão, C. T. P., & dos Santos, J. C. C. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102514 · Cited by 37
Metadata
- Authors
- Richardson, K., Loke, Y. K., Fox, C., Maidment, I., Howard, R., Steel, N., Arthur, A., Boyd, P. J., Aldus, C., Ballard, C., & Savva, G. M.
- Affiliations
- University of East Anglia (GB)
- Aston University (GB)
- University College London (GB)
- University of Exeter (GB)
- Corresponding author
- Richardson, Kathryn
- ORCID
- Venue
- BMC Medicine
- Published
- 2020-11-24
- Volume
- 18
- Issue
- 1
- Pages
- 351-351
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC7683259
- OpenAlex
- W3097629622
- Cited by
- 73
- References
- 67
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 13 · 2023: 8 · 2022: 12 · 2021: 4 · 2020: 1
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Aston Publications Explorer (Aston University) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Open Research Exeter (University of Exeter) (submittedVersion, cc-by)
- Funders
- Health Technology Assessment Programme (14/221/02)
- National Institute for Health Research
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Z-drugs, zopiclone, zaleplon, zolpidem, dementia, sleep disorders, benzodiazepines, adverse drug reactions, falls, hip fracture, fracture risk, ischemic stroke, venous thromboembolism, mortality, dose-response relationship, older adults, Clinical Practice Research Datalink, Hospital Episode Statistics
- MeSH terms
- Zolpidem, Acetamides, Aged, 80 and over, Dementia, Female, Humans, Male, Piperazines, Pyrimidines, Sleep Wake Disorders, Cohort Studies, Azabicyclo Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. https://app.cochat.ai/papers/10.1186/s12916-020-01821-5
- The paper
- Richardson, K., Loke, Y. K., Fox, C., Maidment, I., Howard, R., Steel, N., Arthur, A., Boyd, P. J., Aldus, C., Ballard, C., & Savva, G. M. (2020). Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. BMC Medicine. https://doi.org/10.1186/s12916-020-01821-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.